Exact Sciences stock outlook improves with Cologuard Plus launch …

2 days ago · The firm's analysis indicates that the launch of Cologuard Plus in late Q1 2025 or early Q2 2025 could significantly impact revenue, with a projected reimbursement rate of $592 …

CouponFollow Extension

$592
OFF

Exact Sciences Stock Outlook Improves With Cologuard Plus Launch …

1 day from now

2 days ago · The firm's analysis indicates that the launch of Cologuard Plus in late Q1 2025 or early Q2 2025 could significantly impact revenue, with a projected reimbursement rate of $592 …

investing.com

$70.00
OFF

Exact Sciences Stock Outlook Improves With Cologuard Plus Launch …

1 day from now

On Tuesday, Wolfe Research maintained a positive outlook on Exact Sciences (NASDAQ: EXAS), reiterating an Outperform rating and a $70.00 price target.The firm's analysis indicates …

investing.com

16%
OFF

Exact Sciences Sees 16% Medicare Boost For Cologuard Plus Stock ...

1 day from now

2 days ago · Wolfe Research reiterated an Outperform rating for Exact Sciences, anticipating a significant impact on revenue from the launch of Cologuard Plus in late Q1 2025 or early Q2 …

investing.com

16%
OFF

Exact Sciences Sees 16% Medicare Boost For Cologuard Plus Stock ...

1 day from now

2 days ago · Wolfe Research reiterated an Outperform rating for Exact Sciences, anticipating a significant impact on revenue from the launch of Cologuard Plus in late Q1 2025 or early Q2 …

investing.com

10%
OFF

Exact Sciences Stock Up 10%, BTIG Raises Target After 16% Price ...

1 day from now

2 days ago · While BTIG's optimistic outlook on Exact Sciences (NASDAQ:EXAS) is reflected in their raised price target, recent InvestingPro data provides additional context for investors. …

investing.com

90%
OFF

Exact Sciences Has An Established Colon Cancer Screening …

1 day from now

Nov 6, 2024 · Cologuard Plus, which was approved in the US in October 2024, improves its specificity to be over 90% (93% in its Blue-C trial). It also demonstrated overall sensitivity of …

morningstar.com

9%
OFF

Exact Sciences Stock Rises After FDA Signs Off On New Cologuard

1 day from now

Oct 4, 2024 · In early trades, Exact Sciences stock rose 1.9% to 67.67. Shares have trended higher since June, though remain far from their record high at 159.54 in January 2021, …

investors.com

16%
OFF

Why Is Exact Sciences Stock Trading Higher On Monday?

1 day from now

1 day ago · Centers for Medicare & Medicaid Services finalizes 2025 pricing for Exact Sciences' Cologuard Plus, raising Medicare reimbursement by 16% and boosting growth projections for …

benzinga.com

43%
OFF

Exact Sciences Stock Rises After FDA Signs Off On New Cologuard

1 day from now

Cologuard Plus also showed 43% sensitivity for finding advanced precancerous lesions. Doctors can remove lesions before they develop into cancer. In early trades, Exact Sciences stock …

msn.com

16%
OFF

EXAS Reaffirms Stock Target, Rating Held On Amid CMS Price Boost

1 day from now

2 days ago · In other recent news, Exact Sciences Corporation has secured a 16% increase in the Medicare rate for its next-generation assay, Cologuard Plus, from the Centers for Medicare & …

investing.com

10%
OFF

Exact Sciences Stock Lifted By TD Cowen, Sees 10% Revenue Growth ...

1 day from now

2 days ago · On Tuesday, TD Cowen demonstrated a positive outlook for Exact Sciences Corp (NASDAQ: EXAS) by increasing the stock's price target from $82.00 to $86.00. The firm has …

investing.com

FAQs about Exact Sciences stock outlook improves with Cologuard Plus launch … Coupon?

Will exact sciences get a higher price for Cologuard plus?

Exact Sciences is now clear to seek Medicare reimbursement on the Advanced Diagnostic Laboratory Tests pathway. Tests must have FDA approval — vs. the lower bar of clearance — to seek reimbursement on the ADLT pathway. Kumar expects the company to ask for a higher price for Cologuard Plus, which will further help Exact Sciences stock. ...

Will Cologuard plus increase its price?

With the anticipated launch of Cologuard Plus in the second quarter of 2025, the price increase is projected to contribute positively to the company’s revenue growth, adding approximately 400 basis points in the second half of 2025 and 200 basis points for the entire year. ...

Is exact sciences (EXAs – research report) a good stock to buy?

Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Brandon Couillard from Wells Fargo maintained a Buy rating on the stock and has a $70.00 price target. Unlock your investing potential with TipRanks Premium - Now At 40% OFF! ...

Should you buy Exact Sciences (Exact Sciences)?

Despite the uncertainty surrounding competitor Freenome’s study outcomes, Mikson’s outlook remains positive on Exact Sciences’ ability to navigate and potentially lead in the CRC screening space. In another report released on March 13, Robert W. Baird also assigned a Buy rating to the stock with a $82.00 price target. ...

Why did exact sciences stock rise Friday?

Exact Sciences stock rose Friday after the FDA approved the company's next-generation colon cancer detection test, Cologuard Plus. ...

Will Cologuard plus improve lab throughput?

The analyst highlights the advancements in Cologuard Plus, which includes additional markers that could improve the false positive rate and increase lab throughput. This innovation is expected to significantly expand the company’s total addressable market (TAM) by about $6 billion. ...